文献速递胸部肿瘤放疗放疗物理与技术

放疗中期PET/CT对III期非小细胞肺癌的预后评估及早期进展检测

Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2017-08-19

该回顾性研究纳入77例接受根治性放疗(伴或不伴化疗)的III期非小细胞肺癌患者,分析放疗前及放疗中期FDG-PET代谢指标与复发、生存的关系。结果显示部分PET指标与局部复发相关,放疗中期PET/CT发现的早期野外进展患者均死亡。

要点

  • 放疗前MTV及放疗中期MTV、TLG与局部复发正相关(p=0.03-0.05)。
  • 放疗中期与放疗前SUVmax比值与区域/远处复发相关(p=0.02)。
  • 放疗中期PET/CT显示早期野外进展者均死亡。

核心结论

  • 部分PET代谢指标与复发风险相关,放疗中期PET/CT发现进展是预后不良因素。

研究设计与样本

  • 回顾性研究纳入77例接受放疗(伴或不伴化疗)的III期非小细胞肺癌患者。
  • 勾画原发肿瘤及受累淋巴结,分析放疗前及放疗中期FDG-PET指标(MTV、TLG、SUVmax)。
  • 采用Cox回归评估PET指标对死亡时间、局部复发及区域/远处复发的影响。

主要发现

  • 91%患者接受同步化疗,中位随访14个月。
  • 所有PET指标均与总生存无关。
  • 放疗前MTV及放疗中期MTV、TLG与局部复发正相关(p=0.03-0.05)。
  • 放疗中期与放疗前SUVmax比值与区域/远处复发相关(p=0.02)。
  • 5/77例放疗中期扫描显示早期野外进展,这些患者均死亡。

临床怎么用

  • 放疗中期PET/CT可用于识别高复发风险及早期进展患者,辅助预后判断。

局限性

  • 回顾性研究,样本量有限,中位随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Pre- and mid-radiotherapy FDG-PET metrics have been proposed as biomarkers of recurrence and survival in patients treated for stage III non-small cell lung cancer. We evaluated these metrics in patients treated with definitive radiation therapy (RT). We also evaluated outcomes after progression on mid-radiotherapy PET/CT. MATERIAL AND METHODS: Seventy-seven patients treated with RT with or without chemotherapy were included in this retrospective study. Primary tumor and involved nodes were delineated. PET metrics included metabolic tumor volume (MTV), total lesion glycolysis (TLG), and SUVmax. For mid-radiotherapy PET, both absolute value of these metrics and percentage decrease were analyzed. The influence of PET metrics on time to death, local recurrence, and regional/distant recurrence was assessed using Cox regression. RESULTS: 91% of patients had concurrent chemotherapy. Median follow-up was 14months. None of the PET metrics were associated with overall survival. Several were positively associated with local recurrence: pre-radiotherapy MTV, and mid-radiotherapy MTV and TLG (p=0.03-0.05). Ratio of mid- to pre-treatment SUVmax was associated with regional/distant recurrence (p=0.02). 5/77 mid-radiotherapy scans showed early out-of-field progression. All of these patients died. CONCLUSIONS: Several PET metrics were associated with risk of recurrence. Progression on mid-radiotherapy PET/CT was a poor prognostic factor.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Gensheimer MF, Hong JC, Chang-Halpenny C, et al. Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. Radiother Oncol. 2017. PMID: 28830717. doi:10.1016/j.radonc.2017.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。